

Fluence

Q2 trading update

Fluence's Q2 statement confirms FY18 guidance and highlights encouraging progress in China. The company still has a lot to deliver in H218, but the fundamentals of its market (the supply of distributed water/wastewater treatment) look very attractive, in our view.

On track to double

Fluence reiterated guidance of \$105-115m in revenues for FY18, a near doubling of pro-forma sales y-o-y. After reporting \$22.6m in Q2, the mid-range of this target implies revenues of \$77m in H218 (\$38.6m per quarter). The timing of revenue recognition on large contracts is hard to predict and, following a miss in Q417, investors may need more evidence of delivery. Nevertheless, this forecast is underpinned by a revenue backlog of \$84m, \$49m of which is expected to be recognised in H2 (predominantly the San Quintin and PDVSA projects), and a very healthy pipeline of business yet to reach the order book.

China momentum building...

The Chinese market has huge long-term growth potential in our view (see <u>China Water Affairs</u>). Fluence has been steadily building up its presence by signing up regional partners and demonstrating the cost effectiveness of its technology. Q2 provided significant evidence of commercial traction with a further three new partners delivering their first sales. Revenue from China is likely to be modest in FY18 (low single-digit millions) but has the potential to expand dramatically in FY19 and beyond, in our view.

...and momentum elsewhere

While no financial details were provided, progress across other regions, particularly Europe and Latin America, and further sales of smart packaged solutions like Nirobox, were also highlighted. The company consumed \$14.2m in cash from operating activities (\$17.7m in total) and expects to consume a further \$13.6m in Q3. We expect the ramp up of San Quintin to bolster cash generation in Q4.

Valuation: Fundamentals factored in

At A\$0.39/share and using Q2 \$40.2m net cash, Fluence trades at 2.7x consensus FY20 EBITDA, a multiple which suggests the market is sceptical about delivery. Reiteration of guidance and China commentary should provide some reassurance. We believe the decentralised water and wastewater treatment solution market has very attractive long-term growth prospects and with a suite of unique IP and global resources. Fluence is well-positioned to address this opportunity.

Consensus estimates						
Year end	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (US\$)	EV/Sales (x)	EV/EBITDA (x)
12/17	58.0	-24.8	-22.9	-7.0	1.5	N/M
12/18e	100.6	-14.4	-17.9	-3.2	0.8	N/M
12/19e	147.0	-2.5	-7.8	-1.4	0.6	N/M
12/20e	267.0	31.5	23.5	4.2	0.3	2.7

Source: Canaccord Genuity (see https://www.fluencecorp.com/investor-news/)


Industrials

30 July 2018

Price A\$0.39 Market cap A\$170m

AUS\$/US\$ = 0.74

Share price graph



Share details

Code FLC
Listing ASX
Shares in issue 435m

Business description

Fluence is a global supplier of waste and fresh water treatment solutions. Its patented MABR and Nirobox technologies provide municipal and industrial customers "plug and play" solutions that aim to be both quicker to deploy and substantially cheaper than traditional alternatives.

Bull

- Rapid acceleration in growth anticipated in H218
- Large untapped opportunity in China
- Order book offering good visibility.

Bear

- Not expected to reach profitability until 2019
- Missed revenue target in 2017
- Low liquidity

Analysts

Dan Gardiner +44 (0)20 3077 5700
Dario Carradori +44 (0)20 3077 5700
Graeme Moyse +44 (0)20 3077 5700

industrials@edisongroup.com

Fluence is a research client of Edison Investment Research Limited



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247555) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc. (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Fluence and prepared and issued by Edison for publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of his report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL-427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to Imagine Use and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser with the Securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their roles as financial advisers or broke